What is the efficacy of percutaneous transcatheter aortic-valve replacement (TAVR) for the treatment of aortic stenosis (AS)?

Updated: May 07, 2019
  • Author: Xiushui (Mike) Ren, MD; Chief Editor: Terrence X O'Brien, MD, MS, FACC  more...
  • Print

In the Placement of Aortic Transcatheter Valves (PARTNER) trial, inoperable patients with severe aortic stenosis had improved survival with TAVR compared with medical management. [36] In high-risk patients, survival was similar with TAVR and surgical aortic valve replacement. In all the patient cohorts, low flow (stroke volume index ≤35 mL/m2) was an independent predictor of mortality, whereas low ejection fraction and mean gradient were not. [36]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!